Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019

被引:2
|
作者
Razonable, Raymund R. [1 ]
Ganesh, Ravindra [1 ]
Bishop, Rachel K. [2 ]
Culbertson, Tracy L. [3 ]
Borgen, Molly Destro [1 ]
Hedin, Michelle C. [1 ]
Hopkins, Laura H. [3 ]
Jackson, Tammy A. [4 ]
Larsen, Jennifer J. [1 ]
Matoush, Jennifer A. [1 ]
Moehnke, Darcie E. [1 ]
Olson, Shelly M. [5 ]
Peterson, Kellie M. [6 ]
Rosedahl, Jordan [1 ]
Philpot, Lindsey M. [1 ]
机构
[1] Mayo Clin, Rochester, MN USA
[2] Mayo Clin Hlth Syst Franciscan Healthcare, La Crosse, WI USA
[3] Mayo Clin Hlth Syst, Mankato, MN USA
[4] Mayo Clin Hlth Syst, Eau Claire, WI USA
[5] Mayo Clin Hlth Syst, Owatonna, MN USA
[6] Mayo Clin Hlth Syst, Albert Lea, MN USA
来源
关键词
COVID-19; monoclonal antibodies; bamlanivimab; casirivimab; infusion; FRAMEWORK;
D O I
10.1177/23743735221105673
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by 644/2412 (26.7% response) individuals evaluated for anti-spike monoclonal antibody therapies, the majority of 523 patients who received the antibody infusion were very satisfied with their overall patient experience, the quality of care provided, and various aspects of medical care. They voiced satisfaction with the communication with providers before and during treatment, including education provided about monoclonal antibody treatment, the potential benefits and adverse effects, detailed instructions on the process of infusion, and safety protocols employed at the infusion facilities. Nearly a quarter (23.6%) of 121 patients who declined therapy indicated they would accept treatment should it be offered again. These patient perspectives may be used to guide healthcare facilities and providers in optimizing the care provided to high-risk outpatients with COVID-19.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
    Thilagar, Bright P.
    Ghosh, Aditya K.
    Nguyen, Jerome
    Theiler, Regan N.
    Wick, Myra J.
    Hurt, Ryan T.
    Razonable, Raymund R.
    Ganesh, Ravindra
    [J]. OBSTETRICS AND GYNECOLOGY, 2022, 139 (04): : 616 - 618
  • [2] Anti-Spike Monoclonal Antibody Therapy in Pregnant Women with Mild-to-Moderate Coronavirus Disease 2019 (COVID-19) (vol 139, pg 616, 2022)
    Matteson, Kristen A.
    Schimpf, Megan O.
    Jeppson, Peter C.
    Thompson, Jennifer C.
    Gala, Rajiv B.
    Balgobin, Sunil
    Gupta, Ankita
    Hobson, Deslyn
    Sheyn, David D.
    Olivera, Cedric
    Singh, Ruchira
    White, Amanda B.
    Balk, Ethan M.
    Meriwether, Kate V.
    [J]. OBSTETRICS AND GYNECOLOGY, 2023, 142 (01): : 220 - 220
  • [3] Evaluation of Serum Antibody Levels and Presence of Neutralizing Antibodies in Patients with Mild and Moderate Coronavirus Disease-2019
    Ozkaya, Esra
    Tosun, Ilknur
    Baran, Irmak
    Buruk, Celal Kurtulus
    Kaklikkaya, Nese
    Aydin, Faruk
    Erturk, Murat
    [J]. MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2022, 11
  • [4] Coronavirus Disease 2019-Related Alterations of Total and Anti-Spike IgG Glycosylation in Relation to Age and Anti-Spike IgG Titer
    Schwedler, Christian
    Grzeski, Marta
    Kappert, Kai
    Rust, Joern
    Heymann, Guido
    Hoppe, Berthold
    Blanchard, Veronique
    [J]. FRONTIERS IN MICROBIOLOGY, 2022, 13
  • [5] Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort
    Nichols, Courtney N.
    Lustberg, Mark
    Sobhanie, Mohammed Mahdee E.
    Niermann, Lucia J.
    Gordon, Melissa
    Kman, Nicholas
    Parsons, Jonathan
    Conroy, Mark
    Dick, Michael
    Allen, James
    Reed, Erica
    Lehman, Joy
    Malvestutto, Carlos
    [J]. ANTIVIRAL THERAPY, 2024, 29 (04)
  • [6] Transient Cardiomyopathy in a Patient With Coronavirus Disease-2019
    Anupama, B. K.
    Thapa, Simant S.
    Amzuta, Ioana
    [J]. JOURNAL OF INVESTIGATIVE MEDICINE HIGH IMPACT CASE REPORTS, 2020, 8
  • [7] Discriminating endogenous vaccine-elicited anti-Spike antibody responses from exogenous anti-Spike monoclonal antibodies: The case of Evusheld
    Focosi, Daniele
    Maggi, Fabrizio
    Shoham, Shmuel
    Casadevall, Arturo
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (01)
  • [8] A Propensity-Matched Cohort Assessing Impact of a Neutralizing Monoclonal Antibody in Mild-to-Moderate Coronavirus Disease 2019
    Abbas, Malak
    Farhat, Nada
    Hammoud, Zainab
    Dickey, Curtis
    Shuayto, Ali
    Chen, Nai-Wei
    Hsaiky, Lama M.
    Sims, Matthew
    Sengstock, David
    Schramski, Joseph
    Shamoon, Zafar
    [J]. JOURNAL OF INTENSIVE CARE MEDICINE, 2023, 38 (06) : 511 - 518
  • [9] An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2
    Focosi, Daniele
    Franchini, Massimo
    Casadevall, Arturo
    Maggi, Fabrizio
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2024, 30 (08) : 999 - 1006
  • [10] Anti-Spike Monoclonal Antibody Monotherapies and Immune Escape Risk Minimization Strategies
    Casadevall, Arturo
    Focosi, Daniele
    [J]. CLINICAL INFECTIOUS DISEASES, 2024,